The Tissue Procurement and Banking Facility (TPBF) is an established CCSG- supported core facility at the MDACC, that provides peer-funded basic science and clinical investigators at this institution with human tumor tissues that have been removed for biopsy or therapeutic resections, for on-going research projects. The TPBF functions to procure virtually all pathologic tumor tissue from patient procedures, that is not used for initial diagnosis, follow-up diagnostic studies, including cryogenically stored for future clinical follow-up. This tumor tissue is obtained to provide fresh, sterile (if requested), well-characterized human tumor specimens expeditiously (, 1 hour), to the wide spectrum of research scientists involved in virtually every type of human tumor investigation. Special preservation procedures will be instituted for nucleic acids and other methodologies for genomic analysis. The TPBF, that stores and triages tumor tissue for disease-site tumor programs, as well as cryopreservation, is being expanded into new, specifically designated and appropriate out-fitted space, to provide for more efficient and inclusive tumor banking facilities. The expanded banking facility will not only provide state-of-the-art cryopreservation facilities, but will also include an interactive database that will provide all pertinent information on tumor specimens procured by the TPBF. It will also interface with other institutional databases (hospital, pathology, epidemiology, etc.) that can provide vital and important data and other pertinent information to the searcher such as confidentiality/security.
The specific aims of this proposal involve: 1) providing a flexible specialized tissue procurement resource providing for the efficient and expeditious delivery of freshly-obtained, well characterized tumor tissue to requesting investigators; 2) to develop a contemporary, centralized institution-wide tumor tissue procurement and banking core facility which will provide tissue compatible with current and predicted methodologies for analysis of DNA, RNA and protein as well as other methods of analysis; 3) to develop an interactive, accessible computer database which will provide epidemiology, family history, patient treatment and patient outcome and 4) to coordinate with existing individual """"""""satellite"""""""", programmatically administered and funded tissue banks currently operational within the institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-25
Application #
6334918
Study Section
Project Start
2000-07-18
Project End
2001-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
25
Fiscal Year
2000
Total Cost
$332,337
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications